Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVTCZ: Tocilizumab vs Cyclophosphamide for Microscopic Polyangiitis and Granulomatosis with Polyangiitis
jRCT1091220325Recruiting
- Sponsor
- Masayoshi Harigai
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of tocilizumab in microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), Pauci-immune glomerulonephritis (PIGN) and 1 more (2 arms), sponsored by Masayoshi Harigai. Primary endpoint: Complete remission at week 24. Started Jan 2018; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)Pauci-immune glomerulonephritis (PIGN)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on jRCT1091220325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220325.